BC Innovations | May 26, 2016
Distillery Techniques

Techniques: Baculovirus-based vector system for transient, simultaneous expression of multiple genes for genome editing or cellular reprogramming

Drug platforms TECHNOLOGY: Expression systems A baculoviral vector-based system for transient gene expression could be used to develop genome editing- or cellular reprogramming-based therapies. The vector system involved modifying baculovirus by inserting a plasmid containing...
BC Week In Review | Oct 7, 2013
Company News

Forest Laboratories, Royalty Pharma, Apotex, Hetero Drugs, Lupin, Mylan, Par Pharmaceutical musculoskeletal news

Forest and Royalty filed suits in the U.S. District Court for the District of Delaware alleging that the generic companies are infringing patents covering Savella milnacipran from Forest to treat fibromyalgia. Forest and Royalty Pharma...
BC Week In Review | Apr 15, 2013
Clinical News

Infusible Platelet Membrane data

Cypress Bioscience Inc. (CYPB), San Diego, Calif.   Product: Infusible Platelet Membrane (IPM)   Indication: Active bleeding   CYPB announced results of a Phase II trial in patients with low platelet counts during active bleeding....
BC Week In Review | Aug 13, 2012
Company News

Forest Laboratories generics, pharmaceuticals news

Forest and Carl Icahn issued dueling statements ahead of the company's Aug. 15 annual meeting, where the activist investor will seek to install his slate of four directors on Forest's board. Icahn claims Forest is...
BC Extra | Aug 10, 2012
Company News

Forest, Icahn trade barbs ahead of showdown

Forest Laboratories Inc. (NYSE:FRX) and Carl Icahn issued dueling statements on Friday ahead of the company's Aug. 15 annual meeting, where the activist investor will seek to install his slate of four directors on Forest's...
BioCentury | Apr 4, 2011
Finance

Eleventh Hour Push

A last minute surge led by large cap stocks enabled biotech indices to post a strong performance for the first quarter. Prior to that, biotech had been relatively flat or down for most of the...
BC Week In Review | Jan 10, 2011
Company News

Cypress Bioscience, Royalty Pharma, Ramius LLC deal

Ramius and Royalty completed their previously announced tender offer for Cypress, acquiring 28.7 million shares (73.6%) at $6.50 per share in cash, or about $186.6 million, to raise the companies' holdings in Cypress to 83.5%....
BioCentury | Jan 10, 2011
Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the...
BC Week In Review | Jan 3, 2011
Company News

Cypress Bioscience, Royalty Pharma, Ramius LLC deal

Ramius and Royalty extended to midnight on Jan. 5, 2011, from Dec. 30, 2010, the deadline for their tender offer to acquire the 90.1% of Cypress that Ramius does not already own for $6.50 per...
BC Week In Review | Dec 20, 2010
Company News

Cypress Bioscience, Royalty Pharma, Ramius LLC deal

Cypress' agreed to a $6.50 per share cash offer by Ramius and Royalty to acquire the 90.1% of Cypress that Ramius does not already own. Ramius said on Dec. 14 that Cypress rejected a $6...
Items per page:
1 - 10 of 209
BC Innovations | May 26, 2016
Distillery Techniques

Techniques: Baculovirus-based vector system for transient, simultaneous expression of multiple genes for genome editing or cellular reprogramming

Drug platforms TECHNOLOGY: Expression systems A baculoviral vector-based system for transient gene expression could be used to develop genome editing- or cellular reprogramming-based therapies. The vector system involved modifying baculovirus by inserting a plasmid containing...
BC Week In Review | Oct 7, 2013
Company News

Forest Laboratories, Royalty Pharma, Apotex, Hetero Drugs, Lupin, Mylan, Par Pharmaceutical musculoskeletal news

Forest and Royalty filed suits in the U.S. District Court for the District of Delaware alleging that the generic companies are infringing patents covering Savella milnacipran from Forest to treat fibromyalgia. Forest and Royalty Pharma...
BC Week In Review | Apr 15, 2013
Clinical News

Infusible Platelet Membrane data

Cypress Bioscience Inc. (CYPB), San Diego, Calif.   Product: Infusible Platelet Membrane (IPM)   Indication: Active bleeding   CYPB announced results of a Phase II trial in patients with low platelet counts during active bleeding....
BC Week In Review | Aug 13, 2012
Company News

Forest Laboratories generics, pharmaceuticals news

Forest and Carl Icahn issued dueling statements ahead of the company's Aug. 15 annual meeting, where the activist investor will seek to install his slate of four directors on Forest's board. Icahn claims Forest is...
BC Extra | Aug 10, 2012
Company News

Forest, Icahn trade barbs ahead of showdown

Forest Laboratories Inc. (NYSE:FRX) and Carl Icahn issued dueling statements on Friday ahead of the company's Aug. 15 annual meeting, where the activist investor will seek to install his slate of four directors on Forest's...
BioCentury | Apr 4, 2011
Finance

Eleventh Hour Push

A last minute surge led by large cap stocks enabled biotech indices to post a strong performance for the first quarter. Prior to that, biotech had been relatively flat or down for most of the...
BC Week In Review | Jan 10, 2011
Company News

Cypress Bioscience, Royalty Pharma, Ramius LLC deal

Ramius and Royalty completed their previously announced tender offer for Cypress, acquiring 28.7 million shares (73.6%) at $6.50 per share in cash, or about $186.6 million, to raise the companies' holdings in Cypress to 83.5%....
BioCentury | Jan 10, 2011
Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the...
BC Week In Review | Jan 3, 2011
Company News

Cypress Bioscience, Royalty Pharma, Ramius LLC deal

Ramius and Royalty extended to midnight on Jan. 5, 2011, from Dec. 30, 2010, the deadline for their tender offer to acquire the 90.1% of Cypress that Ramius does not already own for $6.50 per...
BC Week In Review | Dec 20, 2010
Company News

Cypress Bioscience, Royalty Pharma, Ramius LLC deal

Cypress' agreed to a $6.50 per share cash offer by Ramius and Royalty to acquire the 90.1% of Cypress that Ramius does not already own. Ramius said on Dec. 14 that Cypress rejected a $6...
Items per page:
1 - 10 of 209